Rivia, a Zurich-based clinical trial intelligence technology company, has launched Data Findings, an AI-powered module designed to automate clinical data reviews and help drug developers resolve problems earlier in the research process. The product expands Rivia’s existing data management platform and aims to reduce delays between the completion of clinical trials and the analysis of study results.
Data Findings operates as an add-on to Rivia Core, a platform that combines information from different clinical trial systems and vendors into a unified data environment.
The new module automates checks involving multiple data sources, allowing clinical research teams to identify inconsistencies and other potential problems while studies remain underway.
Clinical trials frequently collect large volumes of patient information across numerous forms, systems, and research sites.
Traditional electronic data capture platforms can identify straightforward entry errors, but more complicated checks involving multiple forms and data types often require specialized programming or manual review.
Rivia developed Data Findings to automate these more complex processes.
Its agentic AI rule builder enables research teams to describe data validation requirements using natural-language instructions rather than writing custom software.
The platform converts those instructions into validation checks that run continuously as clinical trial information changes.
AI agents then identify, group, and prioritize findings for clinical teams to review.
The product also maintains version controls, approvals, and audit records designed to support data integrity and regulatory oversight.
Rivia believes this approach can reduce the amount of data cleanup required after the last patient completes a clinical study.
Scancell, a UK-based clinical-stage biotechnology company developing cancer immunotherapies, is serving as a design partner and the first adopter of Data Findings.
The company expects to reduce its end-of-study data cleaning period from eight weeks to approximately two weeks.
That projected six-week improvement could allow Scancell to complete database lock procedures earlier, provided the expected operational improvements are achieved.
The product launch comes as clinical trial data volumes continue increasing.
According to research from the Tufts Center for the Study of Drug Development cited by Rivia, Phase 3 studies collect an average of 5.9 million data points per protocol.
The research also indicates that data volumes have increased approximately 11% annually since 2020.
Delays can create significant financial consequences for pharmaceutical developers, particularly when they affect the timing of regulatory submissions or potential product commercialization.
Rivia is using artificial intelligence to help clinical teams detect issues throughout the study rather than concentrating substantial review work at the end.
In March 2026, the company secured an oversubscribed $15 million Series A funding round led by Earlybird Venture Capital.
The financing included participation from Defiant and existing investors Speedinvest, Amino Collective, and Nina Capital.
The investment is supporting the expansion of Rivia’s clinical trial intelligence platform and embedded AI capabilities.
The introduction of Data Findings extends the company’s efforts to improve clinical data quality, reduce repetitive work, and accelerate the development of new medicines.
KEY QUOTES
“The increasing complexity of drug development requires a fundamentally different approach to clinical data infrastructure. Unresolved data issues regularly delay the transition from clinical trial completion to data analysis and regulatory submission up to several months. Through real-time, automated review of clinical trial data, Data Findings helps clinical teams flag issues during the study, rather than leave them for the final clean-up.”
Erik Scalfaro, CEO And Co-Founder Of Rivia
“Adopting Rivia’s AI-driven clinical data analysis tool Data Findings has enabled Scancell to translate its Phase 2 clinical trial data with greater granularity, confidence and efficiency. Furthermore, this has facilitated in-study data cleaning and quality checks such that we expect to reach Last Patient Last Visit (LPLV) with substantially improved data quality and the potential to bring forward end-of-study database lock by six weeks.”
Joe Thornton, Vice President Of Clinical Operations At Scancell

